Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) EBT (2016 - 2026)

United Therapeutics' EBT history spans 17 years, with the latest figure at $444.0 million for Q4 2025.

  • On a quarterly basis, EBT rose 11.98% to $444.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 11.36% increase, with the full-year FY2025 number at $1.7 billion, up 11.36% from a year prior.
  • EBT hit $444.0 million in Q4 2025 for United Therapeutics, up from $438.0 million in the prior quarter.
  • Over the last five years, EBT for UTHR hit a ceiling of $444.0 million in Q4 2025 and a floor of $32.5 million in Q1 2021.
  • Historically, EBT has averaged $303.6 million across 5 years, with a median of $323.8 million in 2022.
  • Biggest five-year swings in EBT: crashed 81.06% in 2021 and later skyrocketed 849.85% in 2022.
  • Tracing UTHR's EBT over 5 years: stood at $140.5 million in 2021, then grew by 27.26% to $178.8 million in 2022, then surged by 65.21% to $295.4 million in 2023, then surged by 34.22% to $396.5 million in 2024, then rose by 11.98% to $444.0 million in 2025.
  • Business Quant data shows EBT for UTHR at $444.0 million in Q4 2025, $438.0 million in Q3 2025, and $408.4 million in Q2 2025.